|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
.
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
The patent application made in the USA regarding the technology developed by our indirect subsidiary Glaucot Teknoloji Anonim Şirketi (www.glaucot.com) , which aims to stop the Glaucoma disease, which causes blindness in its advanced stages, without surgery and medication, has been concluded positively and the patent certificate number 11.903.880 B2 dated 20 February 2024 has been issued.
We present it to the information of our shareholders and the public.
|
||||||||